Non-invasive liver profile testing

Developed by scientists at the VIB University of Ghent, Belgium, the Glyco Liver Profile test from Helena Biosciences is the first of its kind delivering a comprehensive picture of chronic liver disease enabling clinicians to diagnose and monitor patients with hepatic inflammation, fibrosis and cirrhosis while providing a prognostic marker of hepatocellular carcinoma (HCC) risk.

The test is conducted utilising capillary electrophoresis on Helena Biosciences’ V8 NEXUS analyser, with patient results displayed on Platinum 5 Touchscreen software. Dr Adam Stephenson, Director of Sales and Marketing at Helena Biosciences, said: “This is a huge year for the Glyco Liver Profile test and for Helena Biosciences. We have a brand new multi-analyte liver marker that has the potential to be a reference test in hospitals around the world.

“This is a truly innovative test utilising glycomic biomarkers to diagnose and predict the stage and prognosis of liver damage, regardless of the aetiology. Given that we have a global installation base known for myeloma and thalassemia testing, this is one more powerful biomarker that we can roll out to the fleet.”

www.helena-biosciences.com/GLP

 

Other news

Learning from history

Upcoming Events

Lab Innovations

NEC, Birmingham (Hall 12)
30-31 October 2019

British Society for Immunology Congress

Arena and Convention Centre, Kings Dock, Liverpool Waterfront, Liverpool L3 4FP
2-5 December 2019

The genomic and molecular revolution in microbiology: in technology we trust (or do we?).

RAF Museum, Hendon, London
14 May 2020

Clinical and Laboratory Haemostasis 2020

STEM/Atrium Conference Centre, Sheffield Hallam University
3-4 June 2020

Latest Issue

Pathology In Practice

Pathology In Practice

Oct 2019

Are you ready for the winter influenza season?

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.